Standard

Modified cells as potential ocular drug delivery systems. / Tennikova, Tatiana; Urtti, Arto.

In: Drug Discovery Today, Vol. 24, No. 8, 08.2019, p. 1621-1626.

Research output: Contribution to journal › Review article › peer-review

Harvard

Tennikova, T & Urtti, A 2019, 'Modified cells as potential ocular drug delivery systems', Drug Discovery Today, vol. 24, no. 8, pp. 1621-1626. https://doi.org/10.1016/j.drudis.2018.12.004

APA

Tennikova, T., & Urtti, A. (2019). Modified cells as potential ocular drug delivery systems. Drug Discovery Today, 24(8), 1621-1626. https://doi.org/10.1016/j.drudis.2018.12.004

Vancouver

Tennikova T, Urtti A. Modified cells as potential ocular drug delivery systems. Drug Discovery Today. 2019 Aug;24(8):1621-1626. https://doi.org/10.1016/j.drudis.2018.12.004

Author

Tennikova, Tatiana ; Urtti, Arto. / Modified cells as potential ocular drug delivery systems. In: Drug Discovery Today. 2019 ; Vol. 24, No. 8. pp. 1621-1626.

BibTeX

@article{9eb0cf63fe314f8291400ba0f8cbc677,
title = "Modified cells as potential ocular drug delivery systems",
abstract = "Drug delivery to ocular targets is problematic, especially in retinal disease treatment. Therefore, targeted drug delivery, prolonged drug action, and minimally invasive treatments are needed. In this review, we describe cell technologies for drug delivery. These technologies are based on genetic engineering and nongenetic-based approaches for cell modification. In principle, cell technologies enable targeted delivery, long drug action, and minimally invasive administration, but they have only been sparsely studied for ocular drug delivery. Herein, these technologies are discussed in the ocular context.",
author = "Tatiana Tennikova and Arto Urtti",
note = "Funding Information: This research was supported from the Government of Russian Federation Mega-Grant 14.W03.031.0025 {\textquoteleft}Biohybrid technologies for modern biomedicine{\textquoteright}. Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
month = aug,
doi = "10.1016/j.drudis.2018.12.004",
language = "English",
volume = "24",
pages = "1621--1626",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "8",

}

RIS

TY - JOUR

T1 - Modified cells as potential ocular drug delivery systems

AU - Tennikova, Tatiana

AU - Urtti, Arto

N1 - Funding Information: This research was supported from the Government of Russian Federation Mega-Grant 14.W03.031.0025 ‘Biohybrid technologies for modern biomedicine’. Publisher Copyright: © 2018 Elsevier Ltd Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/8

Y1 - 2019/8

N2 - Drug delivery to ocular targets is problematic, especially in retinal disease treatment. Therefore, targeted drug delivery, prolonged drug action, and minimally invasive treatments are needed. In this review, we describe cell technologies for drug delivery. These technologies are based on genetic engineering and nongenetic-based approaches for cell modification. In principle, cell technologies enable targeted delivery, long drug action, and minimally invasive administration, but they have only been sparsely studied for ocular drug delivery. Herein, these technologies are discussed in the ocular context.

AB - Drug delivery to ocular targets is problematic, especially in retinal disease treatment. Therefore, targeted drug delivery, prolonged drug action, and minimally invasive treatments are needed. In this review, we describe cell technologies for drug delivery. These technologies are based on genetic engineering and nongenetic-based approaches for cell modification. In principle, cell technologies enable targeted delivery, long drug action, and minimally invasive administration, but they have only been sparsely studied for ocular drug delivery. Herein, these technologies are discussed in the ocular context.

UR - http://www.scopus.com/inward/record.url?scp=85058979975&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2018.12.004

DO - 10.1016/j.drudis.2018.12.004

M3 - Review article

C2 - 30562585

AN - SCOPUS:85058979975

VL - 24

SP - 1621

EP - 1626

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 8

ER -

ID: 70943192